Literature DB >> 18382889

Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study.

Maarit Tanskanen1, Terhi Peuralinna, Tuomo Polvikoski, Irma-Leena Notkola, Raimo Sulkava, John Hardy, Andrew Singleton, Sari Kiuru-Enari, Anders Paetau, Pentti J Tienari, Liisa Myllykangas.   

Abstract

BACKGROUND: Senile systemic amyloidosis (SSA) is characterized by deposition of wild-type transthyretin (TTR)-based amyloid in parenchymal organs in elderly individuals. Previously, no population-based studies have been performed on SSA.
METHODS: Here we have studied the prevalence and risk factors for SSA in a Finnish autopsied population aged 85 or over, as part of the population-based Vantaa 85+ Autopsy Study (n = 256). The diagnosis of SSA was based on histological examination of myocardial samples stained with Congo red and anti-TTR immunohistochemistry. The genotype frequencies of 20 polymorphisms in 9 genes in subjects with and without SSA were compared.
RESULTS: The prevalence of SSA was 25%. SSA was associated with age, myocardial infarctions, the G/G (Val/Val) genotype of the exon 24 polymorphism in the alpha2-macroglobulin (alpha2M), and the H2 haplotype of the tau gene (P-values 0.002, 0.004, 0.042, and 0.016).
CONCLUSION: This population-based study shows that SSA is very common in old individuals, affecting one-quarter of people aged over 85 years. Myocardial infarctions and variation in the genes for alpha2M and tau may be associated with SSA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18382889     DOI: 10.1080/07853890701842988

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  124 in total

1.  Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).

Authors:  Jacquelyn L Sikora; Mark W Logue; Gloria G Chan; Brian H Spencer; Tatiana B Prokaeva; Clinton T Baldwin; David C Seldin; Lawreen H Connors
Journal:  Hum Genet       Date:  2014-11-04       Impact factor: 4.132

2.  Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy.

Authors:  L H Connors; G Doros; F Sam; A Badiee; D C Seldin; M Skinner
Journal:  Amyloid       Date:  2011-06       Impact factor: 7.141

3.  Role of imaging in cardiac amyloidosis: An ongoing challenge.

Authors:  Ashutosh D Wechalekar
Journal:  J Nucl Cardiol       Date:  2015-11-05       Impact factor: 5.952

4.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis.

Authors:  João L Cavalcante; Shasank Rijal; Islam Abdelkarim; Andrew D Althouse; Michael S Sharbaugh; Yaron Fridman; Prem Soman; Daniel E Forman; John T Schindler; Thomas G Gleason; Joon S Lee; Erik B Schelbert
Journal:  J Cardiovasc Magn Reson       Date:  2017-12-07       Impact factor: 5.364

Review 5.  Cardiac aging and heart disease in humans.

Authors:  Marja Steenman; Gilles Lande
Journal:  Biophys Rev       Date:  2017-03-20

6.  Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease.

Authors:  Sandra Ihne; Caroline Morbach; Claudia Sommer; Andreas Geier; Stefan Knop; Stefan Störk
Journal:  Dtsch Arztebl Int       Date:  2020-03-06       Impact factor: 5.594

7.  Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.

Authors:  Adil Yunis; Gheorge Doros; Ivan Luptak; Lawreen H Connors; Flora Sam
Journal:  Am J Cardiol       Date:  2019-04-09       Impact factor: 2.778

Review 8.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

Review 9.  Novel drugs targeting transthyretin amyloidosis.

Authors:  Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2014-03

10.  Emerging Topics Update of the Brazilian Heart Failure Guideline - 2021.

Authors:  Fabiana G Marcondes-Braga; Lídia Ana Zytynski Moura; Victor Sarli Issa; Jefferson Luis Vieira; Luis Eduardo Rohde; Marcus Vinícius Simões; Miguel Morita Fernandes-Silva; Salvador Rassi; Silvia Marinho Martins Alves; Denilson Campos de Albuquerque; Dirceu Rodrigues de Almeida; Edimar Alcides Bocchi; Felix José Alvarez Ramires; Fernando Bacal; João Manoel Rossi Neto; Luiz Claudio Danzmann; Marcelo Westerlund Montera; Mucio Tavares de Oliveira Junior; Nadine Clausell; Odilson Marcos Silvestre; Reinaldo Bulgarelli Bestetti; Sabrina Bernadez-Pereira; Aguinaldo F Freitas; Andréia Biolo; Antonio Carlos Pereira Barretto; Antônio José Lagoeiro Jorge; Bruno Biselli; Carlos Eduardo Lucena Montenegro; Edval Gomes Dos Santos Júnior; Estêvão Lanna Figueiredo; Fábio Fernandes; Fabio Serra Silveira; Fernando Antibas Atik; Flávio de Souza Brito; Germano Emílio Conceição Souza; Gustavo Calado de Aguiar Ribeiro; Humberto Villacorta; João David de Souza Neto; Livia Adams Goldraich; Luís Beck-da-Silva; Manoel Fernandes Canesin; Marcelo Imbroinise Bittencourt; Marcely Gimenes Bonatto; Maria da Consolação Vieira Moreira; Mônica Samuel Avila; Otavio Rizzi Coelho Filho; Pedro Vellosa Schwartzmann; Ricardo Mourilhe-Rocha; Sandrigo Mangini; Silvia Moreira Ayub Ferreira; José Albuquerque de Figueiredo Neto; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2021-06       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.